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Abstract: In cancers of hormone-dependent organs like women breast and reproductive organs,
endometrium and ovaries, and men’s prostate and testicular cancer, the roles of sex
hormones and deregulation of hormone axes are well-documented. More strikingly,
epidemiological data highlights significant differences between sexes in the incidence
of various cancers in non-reproductive organs, where the role of sex hormones has
been less studied. In an era when personalised medicine is gaining recognition,
understanding molecular, cellular and biological differences between men and women
is timely for developing more appropriate therapeutic interventions according to
gender. In this review we show that sex hormones also shape much of the deregulated
cellular and molecular pathways leading to cell proliferation and cancer in non-
reproductive organs.
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Covilhã, 25th March 2020 
 
Dear Dr Matthew BEYMER  
The authors of the review article entitled “The sex bias of cancer” wish that it is considered 
for publication in Trends in endocrinology and metabolism.  This review highlights the 
differences in cancer onset and progression between men and women in non-
reproductive organs and attempts to explain these differences in the light of 
mechanisms regulated the sex hormones in the organs analyzed. Despite the clear 
differences in cancer prevalence between sexes this is still a largely unexplored subject 
and hope that this review will raise the interest in the study of the role of sex hormones 
in carcinogenesis in non-reproductive organs. We also hope that we were able to meet 
the high standards of TEM to have our work accepted for publication.  
Yours sincerely,  
 
 
Dr Cecília Santos, PhD 
Associate Professor of Health Sciences with Habilitation in Biomedicine 
Health Sciences Research Centre of University of Beira Interior (CICS-UBI), Av. Infante D. 




● Men are more prone to cancer onset and progression in non-reproductive 
organs than women 
● The effects of sex hormones on the hallmarks of cancer depend on the 
target organs and studies often show divergent findings 
● Sex hormone receptors, as well as hormonal levels, often correlate with 
cancer progression in non-reproductive organs 
● Despite the clear sex bias of cancer, the mechanisms regulated by sex 
hormones that might explain the differences  observed in cancer onset and 
progression between men and women are still poorly understood and 
upcoming studies should always distinguish between data obtained from 
men and women, and potentially address the effects of sex hormones on 
mechanisms known to activate carcinogenesis, either in vivo in animal 
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In cancers of hormone-dependent organs like women breast and reproductive 
organs, endometrium and ovaries, and men’s prostate and testicular cancer, the 
roles of sex hormones and deregulation of hormone axes are well-documented. 
More strikingly, epidemiological data highlights significant differences between 
sexes in the incidence of various cancers in non-reproductive organs, where the 
role of sex hormones has been less studied. In an era when personalised 
medicine is gaining recognition, understanding molecular, cellular and biological 
differences between men and women is timely for developing more appropriate 
therapeutic interventions according to gender. In this review we show that sex 
hormones also shape much of the deregulated cellular and molecular pathways 
leading to cell proliferation and cancer in non-reproductive organs.   
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1. Cancer in non-reproductive organs is sex-biased 
Despite the progress in diagnosis and therapy, the global cancer burden is still 
daunting. Recent reports from the World Health Organization show that cancer 
new cases and deaths have risen to 18.1 million and 9.6 million in 2018, 
respectively.  
In Europe, the incidence pattern (Figure 1) is dominated by prostate and breast 
cancers in men and women, respectively, followed by lung and colorectal 
cancers. Bladder, stomach, and kidney cancers also contribute to these figures, 
especially in men, while in women cervical and uterine cancers also have 
incidences greater than 10 cases per 100,000 persons. Breast, prostate and 
colorectal cancers account for half of all cancers in Europe. These data also show 
that there are clear gender differences in the incidence and mortality caused by 
tumours originated in different non-reproductive organs, particularly lung, 
colorectal, bladder, stomach, kidney, pancreas and thyroid gland cancers. Of 
these, only thyroid cancer has higher incidence in women [1]. 
This review correlates the effects of sex hormones (SHs) and their receptors in 
the regulation of the mechanisms underlying the onset and progression of 
cancers in non-reproductive organs to explain the cancer sex-bias put in evidence 
by epidemiological data. 
 
Cancers of the Digestive Tract 
 Esophageal Cancer 
The incidence of esophageal cancer (EC) is 3-4 times higher in men than in 
women [2]. Large population studies support a protective action of estrogens 
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against EC. Other population-based studies (Box 1) also analysed the presence 
and abundance of estrogen receptors (ER; see Glossary) α and β in EC 
biopsies. In a study where EC patients also presented lower levels of estradiol 
(E2) [3],  the expression of ERβ was approximately twice that of ERα, and was 
higher in the primary stages of the lesions. Moreover, the number of ERβ positive 
cells correlated positively with worst prognosis. In another study, ERα and ERβ 
mRNA expression were significantly higher in EC tumour tissues and correlated 
inversely with survival outcome. Upregulation of ERα mRNA correlated with 
higher pathological T-stage and lymph node metastasis, while ERβ mRNA 
upregulation correlated with positive vascular invasion [4]. 
In vitro studies performed in an EC cell line model (ECGI-10) showed that E2 or 
the ERβ-specific agonist diarylpropionitrile stimulated proliferation of ERβ 
transfected cells but had no effect on the proliferation of ERα-transfected cells  
[3]. At first, these findings raise a contradiction with populational studies, where 
estrogens seem to protect against EC, or they may suggest that the anti-cancer 
effects of estrogens are not mediated by ER stimulation, as ERβ-expressing EC 
cells might not be protected from carcinogenesis. Concurrently, in other cell 
models of EC (OE33 and OE19 cell lines), a concentration-dependent inhibition 
of proliferation was induced by a highly selective ERα antagonist and an ERβ-
specific antagonist through stimulation of apoptotic caspase activity and induced 
cell death [4]. Thus, the anti-cancer effect of E2 in EC might be independent from 
ER activation and require that ERs are expressed at lower levels. In line with 
these findings, other authors have proposed that the anti-proliferative effect of 
estrogens may rely on 2-methoxy E2 (2-ME), an endogenous E2 metabolite with 
anti-tumour activities. In vitro studies performed in well-differentiated EC9706 
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cells showed an antiproliferative effect of 2-ME resulting from increased 
apoptosis, accompanied by cell cycle blockade in the G2/M phase [5]. Other 
studies with this compound reinforce its pro-apoptotic effect by increasing the 
Bax/Bcl-2 ratio [6]. In addition, in Barret's esophageal adenocarcinoma, 2-ME 
also lead to a reduction in the migratory/invasive cell behaviour mediated by β-
catenin/E-cadherin signalling pathways [7]. Concurrently, a new water-soluble 
prodrug of 2-ME2 proved to be effective as antiproliferative and anticancer agent 
in both in vitro and in vivo studies and showed great potential in inhibiting the EC 
xenografts’ growth. The anticancer effect of 2-ME2 and its prodrug derivative is 
likely to result from disruption of the microtubule network [8]. Also, an estrogen 
analogue compound (ESE-16) has been designed and tested for in vitro 
antiproliferative potential in an EC cell line and was able to decrease cell density, 
induce metaphase blockage and increase autophagy and activate the intrinsic 
pathway of apoptosis [9]. 
On the other hand, the balance between the estrogenic and androgenic 
environment may also result from disruption of androgenic pathways. Some 
studies have demonstrated that androgen receptors (ARs) are also expressed 
in esophageal tumours [10], but information on in vivo and in vitro AR signalling 
in EC is still very scarce. Even so, the evidences suggest that androgens favour 
proliferation and that this effect is consistent with receptor expression patterns. 
The first in vitro study showing that EC cell lines respond to androgens was 
performed using dihydrotestosterone (DHT) stimulation. It was shown that 
lower DHT concentrations lead to the proliferation of AR-expressing cell lines and 
induced changes in the expression of androgen-responsive genes. These results 
were dependent on the concentration of DHT or the presence of a permissive 
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microenvironment, consistent with similar observations in tumoral tissues [11]. 
However, analysis of the expression of AR in human biopsies have been 
inconclusive and divergent [12].  
 
Gastric Cancer 
The incidence of gastric cancer (GC) is twice as high in men than women. One 
of the main risk factors is Helicobacter pilori infection, which also seems to have 
a preference for the male stomach [13]. A review paper has attempted to find an 
explanation for the predominance of the disease among men, considering that it 
relies on the low estrogen levels, compared to women, as higher long-life 
exposure to estrogens reduces the risk of GC (Box 1). These observations were 
corroborated by an ovariectomized female mice study that presented higher risk 
of GC, which decreased with estrogen treatment [3].  
The protective effects of estrogens, however, seem to depend on estrogen 
receptors, since both ERα and ERβ are present in the gastric mucosa. Although 
some researchers have shown that ERβ is more abundant in GC tumours, both 
ERα and ERβ are expressed therein [3]. The mechanism underlying this 
protection against GC appears to be associated with increased expression of 
trefoil factor proteins that protect the mucosa, and inhibit c-erb-2 oncogene 
expression [3]. A study on a Chinese population with GC demonstrated that ERα 
inhibition reduced GC cell proliferation, migration and invasion by modulating the 
expression of p53, p21, p27, cyclin D1 and E-cadherin, highlighting a direct 
association between ERα-positive GC and worse prognosis, which may perhaps 
be used as a prognostic marker and/or as a therapeutic target [19]. 
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ERα36 is a variant of the full-length 66 kDa ERα66, which lacks the transcriptional 
activation domains (AF-1 and AF-2) but retains the partial dimerization and 
ligand-binding domains and DNA-binding domain, mediating non-genomic effects 
of estrogens important for invasion and metastasis to lymph nodes. In a study of 
45 GCs samples analysed by real time PCR, decreased ERα36 expression levels 
correlated with increased tumour size [14]. Contrastingly, studies using SGC7901 
cells, revealed increased cell proliferation associated with non-genomic effects of 
E2 mediated by ERα36, resulting from the activation of the c-Src signalling 
pathway [3,15]. Moreover, high ERα36 expression levels in these cells resulted 
in estrogen hypersensitivity, high growth rates, and high levels of cyclin D1 unlike 
ERα36-silenced cells [16]. ERα36 silencing in SGC7901 cells reduced the levels 
of phosphorylated glucose regulated protein 94 and Akt. Therefore, the Akt 
signalling pathway is potentially relevant in ERα36-GRP94-mediated gastric 
carcinogenesis [15]. Contrastingly, it was shown that ERα overexpression 
inhibited proliferation, blocked cell entry into G1/G0, promoting apoptosis and 
reducing invasive capacity of GC cells, perhaps due to a decrease in β-catenin 
[15].  
In a 2014 study, Yi et al. demonstrated that E2 increased proliferation in ERα-
positive cells but has no effect on ERα-negative cells. When ERα was inhibited 
by fulvestrant and siRNA, E2-induced proliferation in ERα-positive cells was 
suppressed, and the ERα suppression by fulvestrant, paclitaxel and siRNA 
increased the expression of E-cadherin, a crucial factor in diffuse type 
carcinogenesis [17]. In opposition, E2 treatment in SGC7901 and BGC823 cells 
expressing ERα36, reduced survival rates and viability due to increased 
apoptosis via caspase-3 activation and decreased in Bcl-2 and Bcl-xl levels [18]. 
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In conclusion, the role of ERα in mediating the effects of E2 on GC is controversial 
and deserves further clarification. 
Regarding ARs, reduction in their levels suppressed migration and invasion as 
well as epithelial-mesenchymal transition [19].  
 
Colorectal Cancer 
Another example of gender bias are colorectal cancers (CRC), which also are 
more prevalent in men than women (Box 1). In mice carrying mutations in the 
adenomatous polyposis coli gene, estrogen protects females from CRC 
development, an effect that is lost upon ovariectomy. Male rats exposed to 
testosterone after orchiectomy are also at higher risk than those that were 
orchiectomized but received placebo treatment only. Testosterone also plays 
similar roles in human CRC [20,21]. Some observations suggest that 
progesterone (P4), rather than E2, appears to reduce the risk of CRC in women 
[22], however the mechanisms underlying these observations are still poorly 
studied. E2 treatment reduces cell proliferation by modulating expression of 
cyclins A and D1 and prevents cell migration by inhibiting expression of 
plasminogen activators and matrix metalloproteinases in the LoVo cell line [23]. 
E2 may also increase apoptosis in COLO-205 human CRC cells by decreasing 
the levels of c-myb and Bcl-2 [24]. In an early CRC animal model (polyposis in 
the rat colon; Pirc), males develop twice as many adenomas as females. In 
addition, male wildtype mice injected with the azoxymethane carcinogen also 
developed more colon adenomas than females. Ovariectomized females showed 
no differences in comparison to males, even when they received P4 and E2 
together or separately. In contrast, the reduction of androgens by castration 
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protected Pirc mice from the development of adenomas, while testosterone 
treatments reversed the effects. As the AR could not be detected in either the 
normal colon or adenomas, these effects were found to be independent of the 
receptor and suggest that testosterone is the principal responsible for differences 
in susceptibility between males and females [25]. 
 
Central Nervous System Tumours 
Men have increased susceptibility to astrocytomas, particularly to primary 
glioblastoma (GBM), the most aggressive form of astrocytoma (Box 3). The 
different hormonal backgrounds between men and women might underlie these 
differences [26]. These tumours are known to express estrogen, progesterone 
and androgen receptors, and generally higher-grade tumours are associated with 
decreased ER expression and increased progesterone receptor (PR) 
expression [27,28]. This is consistent with a study where higher PR expression 
was associated with poorly differentiated tumours like GBM and anaplastic 
astrocytoma, in contrast to the low levels of PR observed in benign astrocytomas 
[27,29].  
Like other tumours, GBM can also deceive the immune system by facilitating its 
self-progression, where P4 may also play an important role because of the 
expression of progesterone-induced blocking factor, an immunomodulatory 
protein involved in immune response regulation in the reproductive system [30]. 
Moreover, an in vivo study showed that P4 caused an increase in tumours and 
infiltration area in the cortex of male rats injected with GBM cells (U-87MG cell 
line), contrarily to animals in which PR was silenced, concluding that 
progesterone favours GBM growth and invasive capacity via PR in this animal 
10 
 
model [29]. In an in vitro study, P4 was combined with temozolomide (TMZ), the 
most commonly used chemotherapeutic agent for GBM treatment, to assess 
whether P4 increases the anti-tumour TMZ effect and reduces its side effects. 
They demonstrated that both P4 and TMZ alone induced tumour cell death, and 
that the combined administration potentiated the TMZ effect. Moreover, an 
analysis of intracellular pathways showed that both P4 alone or in combination 
with TMZ suppressed the PI3K/Akt/mTOR pathway and the expression of O-6-
methylguanine-DNA methyltransferase-DNA repair protein in U-87MG cells, 
suppressing cell proliferation and migration [29]. More recently, three studies 
carried out in animal models evaluated the effects of P4 or its analogues. Elmaci 
et al. (2019) demonstrated that medroxyprogesterone acetate inhibited the 
tumour growth in a C6 rat glioma cell model, an effect that was increased by 
tibolone (P4 analogue) and TMZ [31]. Similar results were obtained in an 
orthotopic GBM mouse model administrated with different P4 concentrations, 
leading to a decrease in tumour size as well as to an increase in animal survival 
[32,33]. In conclusion, the effects of P4 on GBM are still controversial: some 
studies report pro-tumour effects while others report anti-tumour actions of P4. 
The differences between these studies might be due to the use of different GBM 
models, hormone concentrations or other experimental conditions. 
Regarding E2, some other evidences suggest that ERα-mediated effects are 
oncogenic, while ERβ-mediated effects function as tumour suppressors. Both 
receptors are present at low levels in primary GBM. A pilot study demonstrated 
that E2 levels were higher in GBM than in grade II and III astrocytoma. However, 
the study also showed that the number of arotamase- and ER-positive cells 
inversely decreased with the tumour malignancy [27]. On the other hand, an in 
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vivo study assessing the action of different concentrations of E2 administration to 
immunodeficient rats previously injected with GBM tumour cells, showed that E2 
increased both male and female rats’ survival, and this effect was observed since 
the early stages of tumour progression, possibly by increasing apoptosis [34].  
Although the highest incidence of brain tumours occurs in men, studies evaluating 
the effects of androgens are extremely rare. A study showed that there is a clear 
AR overexpression in GBM compared to adjacent non-tumour tissues. AR 
expression was also detected in 8 GBM cell lines, in particular U-87MG, in which 
the pro-apoptotic and anti-proliferative effect of transforming growth factor beta 
was reduced by DHT, suggesting that the AR-mediated signalling pathway 
promotes GBM tumorigenesis [28]. More recently, an increase in cell migration, 
invasion and proliferation was observed in three GBM cell lines incubated with 
increasing testosterone concentrations [35]. 
 
Thyroid Cancer 
Thyroid cancer (TC) is 2.9 times more common in women than in men, although 
less aggressive subtypes are more common in women (Box 3). Gender disparity 
in incidence, aggressiveness and prognosis is well-established for this type of 
cancer, but the underlying causes are still poorly studied. Despite the higher 
levels of TC found in women, population-based studies show that reduced 
estrogen exposure favour TC malignancies [40]. These observations suggest that 
broader exposure to female SHs may prevent the disease, but the underlying 
mechanisms remain unclear. However, other studies claim that the higher 
incidence of TC in women may also be related to estrogen signalling. Hydrogen 
peroxide (H2O2) is produced in large quantities in the thyroid and regulates cell 
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proliferation, migration, survival and death, and there are evidences of sexual 
dimorphism in the redox balance of thyrocytes characterized by high production 
of H2O2 due to high expression of inflammatory proteins, accompanied by a 
weakened thyroid antioxidant enzyme, activity in both TC cells (PCCL3) and 
female adult rats. These data suggest that estrogen-induced redox imbalance 
may contribute to thyroid dysfunction, including cancer [36]. A recent review 
summarizes current knowledge of the mechanisms underlying the effects of E2 
on TC [12]. Findings supporting a carcinogenic effect of estrogens on TC cells 
include the hormonal activation of the PI3K pathway and the repression of p27 
expression, via the non-genomic pathway associated with the G protein-coupled 
receptor 30, thus inducing cell proliferation by increasing c-Fos and cyclins A and 
D1 [12]. However, signalling may also involve nuclear receptors ERα and ERβ. 
Kumar et al. suggested that E2 favours ERα expression over ERβ, contributing 
to TC cells proliferation and growth [37]. This imbalance can alter the overall 
behaviour of TC cells, giving them the ability to proliferate and survive by 
increasing ERK1/2 activity [38]. Therefore, the ERs ratio on TC can provide a 
better view of prognosis as well as development of new and more efficient 
therapeutic strategies [12]. Indeed, histological studies on TC show a difference 
in the expression of ER subtypes and that the response of cells to estrogen is 
dependent on the specific ER expressed in TC cells. However, what determines 
tumour-specific SH receptor expression is unclear [39]. Estrogens promote stem 
cell renovation and as such may be involved in tumour initiation and induction of 
cell proliferation and stem cell differentiation in thyroid papillary cancers both in 
vitro and in vivo. Mice inoculated with papillary TC stem cells develop larger 
tumours than controls when treated with E2. The cells' own ability to migrate is 
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stimulated by E2 pre-treatment, allowing these cells to migrate to organs farther 
than vehicle treated cells [40]. These observations may at least partially justify 
the higher incidence of TC in women. 
 
Kidney Cancer 
A potential hypothesis to explain the higher susceptibility of men to kidney cancer 
(KC) (Box 2) relies on X chromosome-encoded genetic mutations, since these 
are more prevalent in male-derived tumours [41]. Gender-specific mutations of 
genes involved in tumorigenesis, like the ubiquitin carboxyl-terminal hydrolase 
BAP1, that promotes protein degradation important for cell survival and death 
have been largely described in KC [42,43].  
A recent review concluded that the inhibition of most sex-related hormonal 
pathways could have an important role in supporting therapies against KC. For 
example, luteinizing and follicle-stimulating (FSH) hormone overexpression 
seems to promote angiogenesis, while FSH alone promotes metastatic formation 
[44]. This study also reported that high levels of glucocorticoid and androgen 
receptors are indicators of tumour suppression. On the other hand, 
overexpression of ERα increases the transcription of the hypoxia-inducible factor 
1-alpha while ERβ has the opposite effect [44]. Concurrently with the 
predominance of KC in men, there is indication that estrogens may have a 
protective role against KC via ERβ, while androgens favour KC cell proliferation. 
Some authors showed that E2 inhibits KC growth through the activation of both 
apoptosis and autophagy pathways [45], and that it triggers DNA repair and 
reactive oxygen species production, thus reducing the viability of KC cells [46]. 
On the other hand, DHT promotes cell proliferation through the activation of signal 
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transducer and activator of transcription 5 via androgen and glucocorticoid 
receptors. Concurrently, the inhibition of these receptors showed antitumor 
activity, highlighting their potential as therapeutic targets in KC [47]. 
 
Bladder Cancer 
Cigarette smoking is the best-established risk factor for bladder cancer (BC) [48–
50], and was considered the major cause of BC in men (Box 2). However, 
smoking habits are not sufficient to explain the effect of gender on BC and urinary 
tract cancers incidence and outcomes, and only a minority of BC cases are 
attributable to environmental exposures [48]. 
Although the bladder is not a sex organ and BC is not considered an endocrine-
related cancer, several authors have agreed that SHs, and particularly their 
binding to receptors, might also contribute for BC development [48–51]. The 
disparities between sexes could be explained by the higher levels of circulating 
androgens in males than females, resulting in increased AR expression and 
signalling, especially at early stages of tumour development and progression [52]. 
Moreover, testosterone can be converted to DHT by the enzyme 5α-reductase in 
BC, although the enzyme expression is lost in higher grade tumours [48]. 
Several authors described the presence of higher levels of AR in tumours and 
metastatic lesions than in control tissues [48–51,53]. AR activation has been 
correlated with chemoresistance in BC cells [51], and AR translocation to the 
nucleus after androgen stimulation can result in the activation of the PI3K/Akt 
pathway activation, known by its central role in cancer progression and pro-
tumorigenic effects [54,55]. Moreover, AR may also promote carcinogenesis 
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through the β-catenin, cyclin-D and EGFR signalling pathways, associated with 
aggressive forms of BC [49]. 
In vivo evidence highlighting a crucial role for AR in BC development and 
progression was obtained in an AR knockout (ARKO) mouse model. In their 
study, only castrated ARKO mice supplemented with DHT and wildtype 
developed N-butyl-N-(4-hydroxybutyl)nitrosamine-induced tumours, but neither 
intact male or female ARKO mice developed BC after 12-weeks of exposure to 
the compound. Moreover, both androgen deprivation and ARKO suppressed cell 
proliferation and increased apoptosis in vitro [48,51,53]. These results were 
corroborated by other authors, who have shown that the AR antagonists 
enzalutamide, flutamide and bicalutamide, inhibited BC incidence and/or 
progression [51]. However, conflicting studies showed no significant correlation 
between AR expression and tumour grade, or even a decrease in AR expression 
with increasing stage of BC [48–51,53]. 
Various single nucleotide polymorphisms have also been associated with 
increased BC risk. For example, a reduction in AR binding affinity to the androgen 
response element on the prostate stem cell antigen gene might stimulate tumour 
growth and metastasis through androgen-independent pathways [48,49]. It has 
been proposed that an earlier loss of AR reactivity may be caused by lower 
androgen levels in women, which in turns leads to more aggressive BC tumours 
[48–50]. These results were corroborated by other studies, where AR expression 
was lost in more advanced BCs, although there was no association with patient 
survival [48–51,53]. 
The overall role of AR in BC remains controversial, and although androgen 
signalling, rather than AR expression levels, may be primarily responsible for the 
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men predisposition to BC, AR expression may be less relevant in females [51,53]. 
Other studies also reported non-androgen-mediated AR activation and non-AR 
pathway androgen-induced bladder tumorigenesis [48,51,53].  
Apart from androgens, estrogens also play important roles in BC development 
and progression, by exerting both stimulatory and inhibitory actions dependent 
on the functional activity of ERα and ERβ [48,53]. Most studies refer that ERα 
loss is associated with BC advanced stages, since it could act as inhibitor of 
tumour development [49,53]. This result was confirmed by a study performed in 
an ERα-knockout mouse model, where the loss of ERα in both male and female 
mice resulted in earlier development and higher incidence of carcinogen-induced 
BC [53].  
ERβ expression is abundant in both normal urothelial and bladder cancer cells, 
and also in both low- and high-grade tumours, irrespective of gender 
[48,49,51,53]. Because of the interactions with various growth factors and its key 
role in several signalling pathways associated with tumorigenesis and cancer 
progression, there might be a correlation between high expression levels of ERβ 
and invasive and high-grade tumours and worse prognosis [48–50,53]. However, 
the role of ERβ in BC remains controversial. Some studies showed an inhibitory 
effect on cell proliferation while others claim that the expression of this receptor 
might promote BC [53,56–58]. In vitro and in vivo experiments showed that ERβ 
knockdown in non-malignant urothelial cells conferred resistance to carcinogens 
[53]. Thus, ERβ has been studied as a potential tumour promotor in BC. 
Several in vitro studies showed that anti-estrogen treatments lead to a reduction 
on BC incidence [48,49,53]. Furthermore, in vivo animal experiments also 
reported that selective ER modulators, like tamoxifen and raloxifene, could inhibit 
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BC progression [48,49,51,53]. The effect of tamoxifen treatment was also 
assessed by two phase II clinical trials (NCT00589017 and NCT02197897), but 
only inconclusive data are still available. Overall, it appears that estrogens may 
protect against or inhibit BC development, but afterwards, at more advanced 
stages they might support tumour progression.  
Although the expression of SH receptors seems to vary according to BC grade, 
they are similarly expressed in males and females, which suggests that gender 
disparities in BC incidence and prognosis might be associated with other factors. 
It has been shown that women at older age at menarche, multiparous, and with 
hormone replacement therapy were at decreased BC risk, contrary to 
postmenopausal women that seem to be at higher risk of BC development [48–
50]. Moreover, gender-specific expression of uridine-5'-diphospho-
glucuronosyltransferases at the molecular level, could lead to differences in the 
degradation of carcinogens, resulting in differential exposure of the urothelium to 
carcinogens [48–50]. Also, glutathione S-transferase M1 expression contributes 
to gender-specific differences in BC risk, since a higher susceptibility was found 
in a null genotype among cigarette-smoking women [48,50]. Sex chromosomal 
roles also have been investigated. Bladder cancer sex differences are unlikely 
associated with the Y chromosome, since its loss increases cancer risk, whereas 
the extra copy of X chromosome among XX individuals is likely to confer better 





The higher incidence of lung cancer (LuC) in men (Box 3) has been largely 
attributed to higher cigarette smoking habits among men but SHs may also have 
their contribution [61]. 
A study performed by Dou et al. (2017) showed that ovariectomized mice with 
decreased hormonal levels as well as significant reduction of protein and mRNA 
expression of SHs receptors, presented increased tumour growth [62]. Also, PR 
expression in tumour-surrounding stromal cells has been associated with 
improved survival for both male and female patients, but the positive PR 
expression in tumour epithelial cells is an independent and unfavourable 
predictor for survival in female patients [63]. An international pooled analysis of 
premenopausal women showed increased risks associated with parity and the 
number of children, that decreased with breastfeeding. Although menstrual and 
reproductive factors may play a role in LuC genesis, smoking remains the most 
important modifiable risk factor [64]. 
Regarding male hormones, higher testosterone or DHT levels have been 
associated with increased LuC incidence, especially in older men, where high 
levels of these hormones predict LuC incidence over the next decade [65]. There 
has also been recently found that androgens and AR promote M2 macrophage 
polarization, associated with asthma and prostate cancer, which might also 
indicate their association with LuC [66]. However, further investigation needs to 
be performed to confirm this hypothesis. 
 
Concluding Remarks and Future Perspectives 
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There are clear differences in the incidence of cancers in non-reproductive 
organs between men and women. Part of these disparities may be attributed to 
the levels of SHs and to SH receptors (Table 1, Key Table).  
Testosterone acts as an inducer of tumour cell proliferation and migration, thus 
often contributing to the highest incidence of most cancers in men. On the other 
hand, female sex hormones P4 and E2 may decrease the proliferation and 
migration of tumour cells, mainly by triggering apoptosis, therefore reducing the 
risk of tumour development in some settings. In particular, the E2 effects, 
depending on the organs might be different or even opposite. In digestive system 
tumours of esophagus, stomach, and colon, E2 decreases cell proliferation, 
associated with enhanced apoptosis and autophagy. In GBM and kidney 
tumours, similar anti-cancer effects of estrogens are described, whereas in 
thyroid and bladder cancers, the effects of estrogens are more controversial 
(Table 1). 
The role of SH receptors has also been studied, and their expression has been 
assessed in tumours of several non-reproductive organs. Most breast cancers 
overexpress ERs and PRs. In breast cancer, receptors are also current 
therapeutic targets that contributed to the increased survival of women with 
hormone receptor-positive breast cancer [67]. Herein we observed that most of 
the tumours in non-reproductive organs also present higher levels or 
overexpression of ERα and ERβ (Table 1). Similar observations were reported 
for AR expression, whose critical role in the prostate cancer is well-established, 
since its increased expression is one of the mechanisms that result in cancer cell 
proliferation [68]. In the non-reproductive organs analysed, ERα appears to be 
more oncogenic than ERβ, particularly in GC and GBM (Table 1). 
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Regarding PR, that has been less studied, there are evidences that its expression 
increases in high-grade tumours. Finally, AR and androgen signalling seem more 
relevant in colorectal and bladder cancers (Table 1). 
Overall, despite the clear differences in the incidence of these cancers between 
men and women, the reasons underneath are still poorly understood (see 
Outstanding Questions). The mechanisms underlying the observed differences 
should be further explored, so that gender-specific targeted therapies can be 
developed against these cancers taking into account not only the sex of the 
individuals but also the hormonal status and the levels of sex hormone receptors 
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Figure 1. Incidence and mortality of the most prevalent cancers in Europe in men 







Box 1. Cancers of the digestive system 
A large population-based study (FINBAR study) showed that higher 
testosterone:estradiol ratios were associated with increased odds of esophagus 
cancer and poorer prognosis [69]. Conversely, women subjected to menopausal 
replacement therapy whether estradiol alone or estradiol plus progestin had 
decreased odds ratio of esophageal carcinomas than non-users, further 
sustaining a protective action of estrogens against esophageal cancer [70]. 
Women with a longer fertile life who have undergone menopausal hormone 
replacement therapy and men with prostate cancer treated with estrogens appear 
to have a decreased risk of gastric cancer [3]. Conversely, women with breast 
cancer treated with tamoxifen, an anti-estrogenic agent, have higher gastric 
cancer risk. Contrastingly, in a study on a Chinese population with gastric cancer, 
ERβ was the most abundant receptor identified, followed by AR and ERα, but 
only ERα and AR expression were associated with decreased patient survival 
[16]. 
Men develop colon adenomas and carcinomas at a younger age and at a higher 
rate than women [25], and the existing data suggests that men are at higher risk 
of developing colorectal cancer due to the influence of testosterone [22].  
Liver cancer is the third most common type of cancer and the second leading 
cause of death in men, who are more susceptible to this cancer than women. One 
of the few sex hormone mediated mechanisms associated with liver cancer 
progression identified, shows that estrogens can have a protective role in the 
incidence of liver cancer by transcriptionally activation of miR23a and p53 via 
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ERα. The expression of miR23a is inversely correlated with the expression of the 
target gene X-linked inhibitor of apoptosis protein, and positively correlated with 
caspase-3/7 activity [71]. 
Incidence of pancreatic cancer is usually higher in men, but the reasons behind 
the prevalence differences observed between sexes are still poorly understood 
[72]. Studies addressing the effects of hormonal contraception did not find any 
significant correlations with the risk of developing pancreatic cancer [73]. 
Conversely, a meta-analysis also concluded that exogenous hormone use, age 
at menarche and/or menopause, hysterectomy, oophorectomy, hormone 
replacement therapy or the oral contraceptives used do not correlate with 
pancreatic cancer [74]. So far, only a Swedish population-based study found a 
significant association between hormone replacement therapy and decreased 
pancreatic cancer risk, especially in women subjected to estrogen-only treatment. 
The same study also showed that higher age at menarche was correlated with 
increased pancreatic cancer risk, suggesting that estrogens have a protective 
role against pancreatic cancer as well [75].  
 
Box 2. Cancers of the urinary system 
Kidney, urothelial carcinomas and bladder cancer are more prevalent in men 
[48,50,51,53]. Men have twice the risk of developing kidney cancer than women. 
This sex disparity has been studied and remained solid across all ages, regions, 
sociocultural habits and health behaviours, suggesting that the incidence 
differences might only be explained by biological differences between genders 
[76]. Despite the higher prevalence of urothelial carcinomas and bladder cancer 
in men, women have lower cancer-specific survival and worse prognosis [49], 
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along with diagnosis at advanced stages of tumours [49,77]. This may be due to 
misdiagnosed symptoms with urinary tract infections, i.e. haematuria, in women 
[48,49]. Several contributors, including genetics, chronic irritation and 
environmental exposures to carcinogens have been proposed for this gender 
disparity, with cigarette smoking being the best-established risk factor for bladder 
cancer [48-50].  
 
Box 3. Other cancers 
Men’s increased susceptibility to astrocytoma, the most common brain tumour, 
and particularly to primary glioblastoma, the most aggressive form of 
astrocytoma, have been well-established since the 1990s. The most recent 
epidemiological data show that the incidence of primary glioblastoma in men is 
50% higher than in women [27,28]. 
Thyroid cancer is the only cancer that affects more women than men. A 
French case-control population study named CATHY analysed the association of 
reproductive and hormonal factors with thyroid cancer among women. This study 
which included 430 papillary thyroid cancer cases and 505 controls demonstrated 
that increased age at menarche and the postmenopausal phase increased the 
risk of thyroid cancer incidence, particularly in cases where menopause resulted 
from an ovariectomy or when women reached menopause before the age of 55. 
Oral contraceptive use and hormone replacement therapy reduced thyroid cancer 
association by about one third and breastfeeding by about 27% [78]. 
Lung cancer has been more incident in men for years. However, over the past 
decades, the number of cases has exponentially increased among women and, 
in turn, cases among men have been declining. There has also been a rapid 
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increase in lung cancer mortality in women compared to men [60]. Both clinical 
and basic research studies support the hypothesis that E2 and cigarette smoking 





Androgen Receptor (AR): type of nuclear receptor that is activated by binding 
any of the androgenic hormones in the cytoplasm and then translocating into the 
nucleus. AR function as a DNA-binding transcription factor that regulate gene 
expression, whose regulated genes are critical for the development and 
maintenance of the male sexual phenotype and skeletal integrity, and for female 
sexual, somatic, and behavioral functions.  
Dihydrotestosterone (DHT): endogenous androgen sex steroid hormone, 
whose formation from testosterone is catalyzed by the enzyme 5α-reductase. It 
is the most potent known endogenous ligand of the androgen receptor. Unlike 
other androgens, DHT cannot be converted by the enzyme aromatase into 
estrogen, thus it is frequently used to distinguish between the effects of 
testosterone and those caused by testosterone's conversion to estradiol. 
17β-Estradiol (E2): estrogen steroid hormone and the major female sex 
hormone, affecting target tissues mainly by interacting with the two nuclear 
estrogen receptors α and β. It is involved in the regulation of the male and female 
reproductive systems, in the neuroprotection of the nervous system, and in other 
tissues like the bone, skin, liver and blood vessels. E2 has also been tied to 
cancer development and progression.  
Estrogen Receptor (ER): steroid hormone receptor found in cells, important in 
sexual maturation and gestation. Two classes of ER exist: nuclear estrogen 
receptors (ERα and ERβ), and membrane estrogen receptors (GPER, ER-X, and 
Gq-mER). In the cytoplasm, once activated by 17β-estradiol, nuclear ERs are 
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able to translocate into the nucleus and bind to DNA to regulate the activity of 
different genes.  
PI3K/Akt Pathway: signal transduction pathway that promotes survival and 
growth in response to extracellular signals. Impairment of PI3K/Akt pathway has 
been linked to a range of diseases, such as cancer, where its upregulation 
promotes cell survival, migration and angiogenesis, cell cycle progression, and 
increased glucose metabolism. 
Progesterone (P4): endogenous steroid and progestogen sex hormone involved 
in the menstrual cycle, pregnancy, and embryogenesis. P4 has a variety of 
important functions in the body, and it is also a crucial metabolic intermediate in 
the production of other endogenous steroids, playing an important role in brain 
function as a neurosteroid.  
Progesterone Receptor (PR): protein found inside cells that is activated by the 
steroid hormone progesterone. In humans, PR has two isoforms PR-A and PR-
B. Once activated upon progesterone binding, the complex enters the nucleus 
and binds to DNA, regulating gene transcription of target genes. 
Testosterone: is the primary male sex hormone and anabolic steroid. In men, 
plays a key role in the development of reproductive tissues, as well as a promoter 
of secondary sexual characteristics. In addition, it is involved in health and well-
being, and in the prevention of osteoporosis. It exerts its action through binding 
to and activation of the androgen receptor. Free testosterone is transported into 
the cytoplasm of target tissue cells or can be reduced to 5α-dihydrotestosterone, 
which binds to the androgen receptor more strongly than testosterone. 
 
Outstanding Questions Box 
 Why cancers in non-reproductive organs have different incidences 
between men and women? 
 What is the impact of sex hormones in cancers of non-reproductive 
organs? 
 How sex hormone receptors correlate with cancer in non-reproductive 
organs? 
Outstanding Questions
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↑β-catenin, cyclin-D1 
and EGFR 




Liver  ↓proliferation       ↑miR23a, ↑p53 [71] 
Pancreas 1.5x  ↓risk in women   ++    [73,74] 
*Incidence Ratio Men:Women              - Not detected               -- Rarely expressed               --- Underexpressed               + Abundant               ++ Highly expressed               +++ Overexpressed  
Abbreviations: ER – estrogen receptor; PR – progesterone receptor; AR – androgen receptor; c-erb-2 – human epidermal growth factor receptor 2; Bax – Bcl-2-associated X protein; Bcl-2 – B-cell 
lymphoma 2; Casp3 – caspase 3; miR23a – microRNA 23a; PI3K – phosphoinositide 3-kinase; ERK1/2 – extracellular signal-regulated protein kinases 1 and 2; UGT – uridine-5'-diphospho-
glucuronosyltransferase; EGFR – epidermal growth factor receptor. 
